top 12 comments

sorted by: hot top controversial new old
[+] 27 points 1 year ago (2 children)
  • load more comments (1 reply)
    [–] 8 points 1 year ago (4 children)

    I mean you gave us Rupert Murdoch and Fox News. So it's a little bit y'all's fault.

  • source
  • hideshow 4 child comments
  • [–] 8 points 1 year ago (2 children)

    Nah mate. Fucker went over there because your systems would facilitate his agenda. You manured that fertile field all by yourselves

  • source
  • parent
  • hideshow 2 child comments
  • [–] 2 points 1 year ago

    Exactly. He knew where the money and propaganda would flow the best. I hate the cunt, but I'd be lying if I said I wasn't at least slightly impressed with the empire he's built. Even if I hate everything about it.

  • source
  • parent
  • [–] 6 points 1 year ago (1 child)
    load more comments (1 reply)
    [–] 5 points 1 year ago (3 children)

    What exactly is this in response to? Like the article goes over all the failings of the US healthcare system that anyone who's paying attention is well aware of, but to what end? Who was saying that Australia had anything to do with the US's healthcare system?

  • source
  • hideshow 3 child comments
  • [–] 7 points 1 year ago (2 children)

    There’s a good explainer article here: https://www.theguardian.com/australia-news/2025/mar/22/us-pharma-trump-australia-pbs-explainer

    It all came up in the tariff negotiations - the PBS in Australia means US drug companies don’t make enough money and/or US citizens are paying more for drugs than Australians.

    Big pharma in the US claims Australians aren’t paying enough for medicines, considering the billions they pour into research and development, and there are too many delays in getting drug approvals.

    PhRMA has asked the Trump administration to put Australia on a “watch list” and wants it to push for change, saying Australia has set the bar too high on cost effectiveness. Australia’s price reductions and “restrictive subsidy caps” meant prices were too low to support investment in innovation, it claims. There are also too many delays in approval processes, it says, adding that the PBS continues to list generic products without the patent owner’s consent.

  • source
  • parent
  • hideshow 2 child comments